Literature DB >> 26573545

Murine and Human Lupus Nephritis: Pathogenic Mechanisms and Theoretical Strategies for Therapy.

Hege Lynum Pedersen1, Kjersti Daae Horvei2, Dhivya Thiyagarajan2, Natalya Seredkina2, Ole Petter Rekvig3.   

Abstract

Lupus nephritis is one of the most serious manifestations of systemic lupus erythematosus, and represents one of the criteria implemented to classify systemic lupus erythematosus. Although studied for decades, no consensus has been reached related to the basic cellular, molecular, and immunologic mechanism(s) responsible for lupus nephritis. No causal treatments have been developed; therapy is approached mainly with nonspecific immunosuppressive medications. More detailed insight into disease mechanisms therefore is indispensable to develop new therapeutic strategies. In this review, contemporary knowledge on the pathogenic mechanisms of lupus nephritis is discussed based on recent data in murine and human lupus nephritis. Specific focus is given to the effect of anti-double-stranded DNA/antinucleosome antibodies in the kidneys and whether they bind exposed chromatin fragments in glomeruli or whether they bind inherent glomerular structures by cross-recognition. Overall, the data presented here favor the exposed chromatin model because we did not find any indication to substantiate the anti-double-stranded DNA antibody cross-reacting model. At the end of this review we present data on why chromatin fragments are expressed in the glomeruli of patients with lupus nephritis, and discuss how this knowledge can be used to direct the development of future therapies.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DNase I; Systemic lupus erythematosus; chaperone molecules; heparin; murine/human lupus nephritis; therapeutic strategies

Mesh:

Substances:

Year:  2015        PMID: 26573545     DOI: 10.1016/j.semnephrol.2015.08.004

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  12 in total

Review 1.  Pathogenesis of proliferative lupus nephritis from a historical and personal perspective.

Authors:  Shu Man Fu; Hongyang Wang; Chao Dai; Sun-Sang J Sung; Felicia Gaskin
Journal:  Clin Immunol       Date:  2016-08-31       Impact factor: 3.969

2.  Class II lupus nephritis with podocyte injury in imiquimod-induced lupus-prone mice.

Authors:  Atsuko Murai; Masaki Yamazaki; Kaori Nishihara; Aki Kito; Sohei Oyama; Naoshi Horiba; Atsuhiko Kato
Journal:  Histol Histopathol       Date:  2022-03-17       Impact factor: 2.130

Review 3.  The Role of Anti-DNA Antibodies in the Development of Lupus Nephritis: A Complementary, or Alternative, Viewpoint?

Authors:  Beatrice Goilav; Chaim Putterman
Journal:  Semin Nephrol       Date:  2015-09       Impact factor: 5.299

Review 4.  [Pathogenesis of systemic lupus erythematosus].

Authors:  S Finzel; S Schaffer; M Rizzi; R E Voll
Journal:  Z Rheumatol       Date:  2018-11       Impact factor: 1.372

5.  Targeted inhibition of Axl receptor tyrosine kinase ameliorates anti-GBM-induced lupus-like nephritis.

Authors:  Yuxuan Zhen; Iris J Lee; Fred D Finkelman; Wen-Hai Shao
Journal:  J Autoimmun       Date:  2018-06-09       Impact factor: 7.094

6.  Acetylated Histones in Apoptotic Microparticles Drive the Formation of Neutrophil Extracellular Traps in Active Lupus Nephritis.

Authors:  Nils Rother; Elmar Pieterse; Jelle Lubbers; Luuk Hilbrands; Johan van der Vlag
Journal:  Front Immunol       Date:  2017-09-14       Impact factor: 7.561

Review 7.  Deoxyribonucleases and Their Applications in Biomedicine.

Authors:  Lucia Lauková; Barbora Konečná; Ľubica Janovičová; Barbora Vlková; Peter Celec
Journal:  Biomolecules       Date:  2020-07-11

8.  Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal.

Authors:  Doua Azzouz; Aidana Omarbekova; Adriana Heguy; Dominik Schwudke; Nicolas Gisch; Brad H Rovin; Roberto Caricchio; Jill P Buyon; Alexander V Alekseyenko; Gregg J Silverman
Journal:  Ann Rheum Dis       Date:  2019-02-19       Impact factor: 19.103

Review 9.  The dsDNA, Anti-dsDNA Antibody, and Lupus Nephritis: What We Agree on, What Must Be Done, and What the Best Strategy Forward Could Be.

Authors:  Ole Petter Rekvig
Journal:  Front Immunol       Date:  2019-05-15       Impact factor: 7.561

10.  Novel AXL-specific inhibitor ameliorates kidney dysfunction through the inhibition of epithelial-to-mesenchymal transition of renal tubular cells.

Authors:  Atsuo Kurata; Yukako Tachibana; Tadakatsu Takahashi; Naoshi Horiba
Journal:  PLoS One       Date:  2020-04-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.